KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Income (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Operating Income for 9 consecutive years, with $260.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 5876.06% year-over-year to $260.4 million, compared with a TTM value of $341.0 million through Dec 2025, up 13508.93%, and an annual FY2025 reading of $341.0 million, up 13508.93% over the prior year.
  • Operating Income was $260.4 million for Q4 2025 at Biocryst Pharmaceuticals, up from $29.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $260.4 million in Q4 2025 and bottomed at -$81.5 million in Q4 2023.
  • Average Operating Income over 3 years is $28.6 million, with a median of $8.8 million recorded in 2024.
  • The sharpest move saw Operating Income skyrocketed 94.47% in 2024, then soared 5876.06% in 2025.
  • Year by year, Operating Income stood at -$81.5 million in 2023, then surged by 94.47% to -$4.5 million in 2024, then skyrocketed by 5876.06% to $260.4 million in 2025.
  • Business Quant data shows Operating Income for BCRX at $260.4 million in Q4 2025, $29.6 million in Q3 2025, and $29.8 million in Q2 2025.